UPC second medical use ruling means off-label use alone won’t prove infringement
Sanofi and Regeneron have lost their infringement case against Amgen in the Unified Patent Court’s first ruling on a second medical use claim, though their patent was upheld as valid. The...To view the full article, register now.
Already a subscriber? Click here to view full article